Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARQT

Arcutis Biotherapeutics Inc

Dec 12 • 04:00PM ET

12.25

Dollar change -0.52
Percentage change -4.07	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN ANAB RCUS BCRX CARA CNTA DERM VERU SLNO KZIA

| Held by: IWM XBI VTI VXF IWO PINK IBB SCHA VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	12.04%	Shs Outstand	117.00M	Perf Week	-0.49%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-1.59%	Shs Float	102.95M	Perf Month	19.51%
Income	-195.53M	PEG	-	EPS next Q	-0.28	Inst Own	103.02%	Short Float	22.85%	Perf Quarter	14.92%
Sales	138.71M	P/S	10.34	EPS this Y	64.44%	Inst Trans	2.76%	Short Ratio	11.70	Perf Half Y	31.16%
Book/sh	1.34	P/B	9.15	EPS next Y	28.16%	ROA	-53.55%	Short Interest	23.53M	Perf Year	494.66%
Cash/sh	2.83	P/C	4.33	EPS next 5Y	9.80%	ROE	-192.31%	52W Range	1.89 - 13.50	Perf YTD	279.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.07%	ROI	-73.92%	52W High	-9.26%	Beta	1.33
Dividend TTM	-	Quick Ratio	2.38	Sales past 5Y	303.42%	Gross Margin	89.43%	52W Low	548.15%	ATR (14)	0.78
Dividend Ex-Date	-	Current Ratio	2.46	EPS Y/Y TTM	59.00%	Oper. Margin	-131.16%	RSI (14)	58.88	Volatility	7.23% 7.23%
Employees	296	Debt/Eq	1.33	Sales Y/Y TTM	182.84%	Profit Margin	-140.97%	Recom	1.29	Target Price	19.00
Option/Short	Yes / Yes	LT Debt/Eq	0.69	EPS Q/Q	53.92%	Payout	-	Rel Volume	0.91	Prev Close	12.77
Sales Surprise	18.98%	EPS Surprise	20.88%	Sales Q/Q	17.44%	Earnings	Nov 06 AMC	Avg Volume	2.01M	Price	12.25
SMA20	6.96%	SMA50	19.98%	SMA200	25.71%	Trades		Volume	1,817,796	Change	-4.07%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Dec-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	Arcutis Announces Promotions on Executive Management Team (GlobeNewswire)
Nov-27-24 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? (Zacks)
09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Nov-20-24 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average (Zacks)
09:30AM	Loading…
09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-19-24 09:55AM	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now (Zacks) +7.00%
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-13-24 08:00AM	Arcutis' ZORYVE (roflumilast) Awarded Best Eczema Treatment by Glamour (GlobeNewswire)
Nov-11-24 09:55AM	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Nov-07-24 02:23AM	Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... (GuruFocus.com) +7.66%
Nov-06-24 05:15PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 07:52AM	Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result (GuruFocus.com) +6.65%
Nov-04-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Loading…
Oct-25-24 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-24-24 08:00AM	Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-23-24 04:00PM	Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference (GlobeNewswire)
Oct-21-24 10:43AM	Health Canada approves Arcutis ZORYVE foam for seborrheic dermatitis (Pharmaceutical Technology)
07:00AM	Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older (PR Newswire)
Oct-18-24 08:20AM	Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older (GlobeNewswire) -8.11%
Oct-12-24 10:18AM	Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments (Insider Monkey)
Oct-09-24 08:03AM	Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT) (Insider Monkey)
Oct-04-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-24 01:00AM	New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types (GlobeNewswire) -5.99%
Sep-24-24 08:00AM	FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Sep-19-24 08:00AM	Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology (GlobeNewswire)
Sep-06-24 01:29AM	Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) (GuruFocus.com)
Sep-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 (GlobeNewswire)
12:01AM	Loading…
12:01AM	Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Aug-22-24 08:00AM	Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-24 01:15PM	Q2 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.27%
Aug-14-24 09:00PM	CORRECTION Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 10:00AM	Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Aug-02-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 04:00PM	Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -5.86%
Jul-29-24 07:35AM	Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. (GlobeNewswire)
07:30AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
08:00AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Jul-22-24 08:00AM	Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL (GlobeNewswire)
Jul-19-24 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-17-24 09:54AM	Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why (Zacks)
Jul-10-24 01:13PM	Arcutis bags FDA approval for atopic dermatitis cream after delay (Pharmaceutical Technology)
11:23AM	FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years (Benzinga)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 04:53PM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age (GlobeNewswire)
08:00AM	Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis (GlobeNewswire)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.27%
Jul-02-24 07:45AM	Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out (Investor's Business Daily)
Jun-17-24 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks) -7.76%
Jun-14-24 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet (Zacks) -7.60%
Jun-13-24 06:00AM	Have $5-10? 7 Affordable Stocks That Are About to Breakout. (InvestorPlace) +15.31%
Jun-10-24 02:30PM	Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-03-24 08:00AM	Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
May-20-24 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade (Zacks)
May-16-24 11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
May-15-24 12:54PM	Q1 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.65%
12:03PM	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday (MT Newswires)
08:53AM	Sector Update: Health Care (MT Newswires)
08:46AM	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating (MT Newswires)
08:19AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
04:24AM	Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket (MT Newswires)
03:13AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-14-24 08:57PM	ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:53PM	Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump (MT Newswires)
04:00PM	Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology (GlobeNewswire)
May-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.98%
Apr-29-24 04:00PM	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire) -5.24%
Apr-10-24 08:00AM	Arcutis Appoints David Topper as Chief Financial Officer (GlobeNewswire)
Apr-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49% +10.49%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-28-24 08:00AM	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-19-24 09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-18-24 09:55AM	Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks)
Mar-11-24 08:00AM	Arcutis Promotes Todd Tucker to Chief Human Resources Officer (GlobeNewswire) -9.96%
Mar-10-24 04:00PM	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-09-24 04:00PM	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction (GlobeNewswire)
Mar-08-24 07:33PM	Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors (Barrons.com) +7.42% -9.96%
Mar-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 04:00PM	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.97%
08:00AM	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks) +14.49%
09:40AM	Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-29-24 05:00PM	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
11:33AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:30PM	Arcutis Announces Pricing of $150 Million Public Offering (GlobeNewswire)
04:10PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Edwards Larry Todd	See Remarks	Nov 30 '24	Buy	7.11	1,093	7,767	137,728	Dec 03 04:17 PM
Matsuda Masaru	See Remarks	Nov 30 '24	Buy	7.11	1,657	11,775	187,030	Dec 03 04:16 PM
Matsuda Masaru	See Remarks	May 31 '24	Buy	1.69	4,000	6,768	185,373	Dec 03 04:16 PM
Welgus Howard G.	Director	Dec 02 '24	Sale	12.51	10,000	125,133	161,944	Dec 03 04:16 PM
Watanabe Todd Franklin	See Remarks	Nov 30 '24	Buy	7.11	2,038	14,482	838,430	Dec 03 04:16 PM
Watanabe Todd Franklin	See Remarks	May 31 '24	Buy	1.69	4,000	6,768	836,392	Dec 03 04:16 PM
Welgus Howard G.	Director	Dec 02 '24	Proposed Sale	12.51	10,000	125,133		Dec 02 04:25 PM
Burnett Patrick	See Remarks	Nov 22 '24	Option Exercise	0.00	16,023	0	144,692	Nov 26 04:21 PM
Burnett Patrick	See Remarks	Nov 22 '24	Sale	10.14	16,023	162,515	128,669	Nov 26 04:21 PM
Burnett Patrick	Officer	Nov 22 '24	Proposed Sale	10.14	16,023	162,515		Nov 22 04:34 PM
Matsuda Masaru	See Remarks	Nov 19 '24	Sale	9.68	1,775	17,190	181,373	Nov 19 07:52 PM
Matsuda Masaru	Officer	Nov 19 '24	Proposed Sale	9.68	1,775	17,190		Nov 19 04:25 PM
Burnett Patrick	See Remarks	Nov 14 '24	Option Exercise	0.00	18,377	0	147,046	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 15 '24	Option Exercise	0.00	100	0	128,769	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 14 '24	Sale	10.29	69,126	711,618	128,669	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 15 '24	Sale	10.03	100	1,003	128,669	Nov 18 07:04 PM
Burnett Patrick	Officer	Nov 15 '24	Proposed Sale	10.03	100	1,003		Nov 15 04:31 PM
Burnett Patrick	Officer	Nov 14 '24	Proposed Sale	10.29	69,126	711,615		Nov 14 04:59 PM
Curran Terrie	Director	Nov 11 '24	Sale	10.85	8,687	94,238	10,139	Nov 13 06:45 PM
Curran Terrie	Director	Nov 11 '24	Proposed Sale	10.85	8,687	94,238		Nov 12 11:34 AM
Matsuda Masaru	See Remarks	Nov 04 '24	Sale	8.68	5,015	43,551	178,273	Nov 05 04:46 PM
Watanabe Todd Franklin	See Remarks	Nov 04 '24	Sale	8.68	13,871	120,459	832,392	Nov 05 04:46 PM
Welgus Howard G.	Director	Nov 01 '24	Sale	8.65	10,000	86,541	171,944	Nov 05 04:46 PM
Burnett Patrick	See Remarks	Nov 04 '24	Sale	8.68	15,441	134,093	179,418	Nov 05 04:45 PM
Watanabe Todd Franklin	Officer	Nov 04 '24	Proposed Sale	8.68	13,871	120,459		Nov 04 04:41 PM
Matsuda Masaru	Officer	Nov 04 '24	Proposed Sale	8.68	5,015	43,551		Nov 04 04:39 PM
Burnett Patrick	Officer	Nov 04 '24	Proposed Sale	8.68	15,441	134,093		Nov 04 04:37 PM
Welgus Howard G.	Director	Nov 01 '24	Proposed Sale	8.65	10,000	86,540		Nov 01 02:51 PM
Welgus Howard G.	Director	Oct 01 '24	Sale	9.26	10,000	92,616	181,944	Oct 03 04:55 PM
Edwards Larry Todd	SVP Chief Commercial Officer	Oct 02 '24	Sale	10.01	3,725	37,295	136,635	Oct 03 04:55 PM
Edwards Larry Todd	Officer	Oct 02 '24	Proposed Sale	10.01	3,725	37,295		Oct 02 04:31 PM
Welgus Howard G.	Director	Oct 01 '24	Proposed Sale	9.26	10,000	92,616		Oct 01 03:32 PM
Topper David Joseph	Chief Financial Officer	Sep 24 '24	Sale	9.48	11,626	110,264	158,374	Sep 25 09:42 PM
Topper David Joseph	Officer	Sep 24 '24	Proposed Sale	9.48	11,626	110,264		Sep 24 03:51 PM
Welgus Howard G.	Director	Sep 03 '24	Sale	10.77	10,000	107,695	191,944	Sep 05 05:56 PM
Welgus Howard G.	Director	Sep 03 '24	Proposed Sale	10.77	10,000	107,695		Sep 03 01:37 PM
Burnett Patrick	See Remarks	Aug 19 '24	Sale	8.29	1,728	14,318	194,859	Aug 21 04:39 PM
Burnett Patrick	Officer	Aug 19 '24	Proposed Sale	8.29	1,728	14,318		Aug 19 05:43 PM
Matsuda Masaru	See Remarks	Aug 02 '24	Sale	9.02	5,220	47,064	183,288	Aug 05 04:37 PM
Burnett Patrick	See Remarks	Aug 02 '24	Sale	9.02	13,206	119,106	196,587	Aug 05 04:37 PM
Watanabe Todd Franklin	See Remarks	Aug 02 '24	Sale	9.02	14,487	130,648	846,263	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Option Exercise	1.68	6,614	11,115	186,953	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Sale	9.87	10,000	98,696	176,953	Aug 05 04:37 PM
Matsuda Masaru	Officer	Aug 02 '24	Proposed Sale	9.02	5,220	47,063		Aug 02 04:22 PM
Burnett Patrick	Officer	Aug 01 '24	Proposed Sale	9.14	13,026	119,105		Aug 02 04:20 PM
Watanabe Todd Franklin	Officer	Aug 02 '24	Proposed Sale	9.02	14,487	130,648		Aug 02 04:19 PM
Welgus Howard G.	Director	Aug 01 '24	Proposed Sale	9.87	10,000	98,696		Aug 01 04:45 PM
Welgus Howard G.	Director	Jul 01 '24	Option Exercise	1.68	10,000	16,806	190,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jul 01 '24	Sale	9.31	10,000	93,141	180,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jun 04 '24	Option Exercise	1.68	10,000	16,806	180,200	Jun 06 04:15 PM
Welgus Howard G.	Director	Jun 04 '24	Sale	8.01	10,000	80,092	170,200	Jun 06 04:15 PM
Burnett Patrick	See Remarks	May 30 '24	Option Exercise	0.00	23,000	0	232,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 29 '24	Sale	8.72	49,952	435,387	209,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 30 '24	Sale	8.75	23,000	201,319	209,793	May 31 04:50 PM
Matsuda Masaru	See Remark	May 28 '24	Sale	9.01	1,775	15,988	188,508	May 29 07:38 PM
Edwards Larry Todd	SVP Chief Commercial Officer	May 17 '24	Sale	8.98	7,640	68,582	140,360	May 20 05:12 PM
Moore Matthew Richard	SVP and Chief Business Officer	May 02 '24	Sale	8.74	4,681	40,902	145,505	May 03 04:29 PM
Watanabe Todd Franklin	See Remarks	May 02 '24	Sale	8.74	13,783	120,433	860,750	May 03 04:22 PM
Matsuda Masaru	See Remark	May 02 '24	Sale	8.74	5,016	43,829	185,408	May 03 04:22 PM
Burnett Patrick	See Remarks	May 02 '24	Sale	8.74	9,555	83,490	259,745	May 03 04:22 PM
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424	Mar 06 05:14 PM
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300	Mar 06 05:12 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533	Mar 06 05:09 PM
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020	Mar 06 05:08 PM
Heron Patrick J	Director	Mar 04 '24	Buy	9.50	21,052	199,994	8,785,284	Mar 06 04:28 PM
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436	Mar 01 04:11 PM
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032	Jan 03 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARQT

Arcutis Biotherapeutics Inc

Upgrade your FINVIZ experience